2023
Cardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman K, Testani J. Cardiorenal interactions in heart failure: insights from recent therapeutic advances. Cardiovascular Research 2023, 120: 1372-1384. PMID: 37364186, PMCID: PMC11472538, DOI: 10.1093/cvr/cvad096.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHeart failureRisk patientsCardiovascular diseaseNew therapiesHigh cardiovascular risk patientsOutcomes of patientsCardiovascular risk patientsChronic kidney diseaseHigh-risk patientsRecent therapeutic advancesSpecific drug classesHigh mortality rateHealth care expendituresCardiorenal continuumCardiorenal interactionsMRA therapyRenal endpointsCardiovascular eventsCardiorenal diseaseKidney diseaseTherapeutic advancesDrug classesTherapeutic approachesMortality ratePatients
2019
Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients
Jain K, Tyagi T, Patell K, Xie Y, Kadado AJ, Lee SH, Yarovinsky T, Du J, Hwang J, Martin KA, Testani J, Ionescu CN, Hwa J. Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients. EBioMedicine 2019, 44: 28-40. PMID: 31130473, PMCID: PMC6604369, DOI: 10.1016/j.ebiom.2019.05.022.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PhysiologicalAge FactorsAgedAged, 80 and overAgingAnimalsAntioxidantsApoptosisBiomarkersBlood PlateletsCardiovascular DiseasesComorbidityDisease Models, AnimalFemaleHomeostasisHumansMaleMiceMiddle AgedOxidation-ReductionOxidative StressPlatelet ActivationPlatelet AdhesivenessReactive Oxygen SpeciesRisk AssessmentRisk FactorsConceptsRisk patientsMouse studiesPlatelet phenotypeMajor adverse cardiovascular eventsHigh cardiovascular risk patientsAdaptive increaseAdverse cardiovascular eventsCentral pathophysiological roleCVD risk patientsCardiovascular risk patientsAggressive antiplatelet therapyEffect of comorbidityAge group 40Young healthy subjectsAntiplatelet therapyCardiovascular eventsYear age cohortAdvanced ageCVD patientsGroup 40Healthy subjectsPathophysiological roleElderly populationCardiovascular pathologyPatients